The Significance of Pain in Chronic Venous Disease and its Medical Treatment
Nema prikaza
Članak u časopisu (Objavljena verzija)
,
© Bentham Science Publishers
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs prov...ed to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.
Ključne reči:
Chronic venous disease / pain / venoactive drugs / hypertension / spinal cord / treatmentIzvor:
Current Vascular Pharmacology, 2019, 17, 3, 291-297Finansiranje / projekti:
- Integralna studija identifikacije regionalnih genetskih faktora rizika i faktora rizika životne sredine za masovne nezarazne bolesti humane populacije u Srbiji - INGEMA_S (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41028)
- Hormonska regulacija ekspresije i aktivnosti azot oksid sintaze i natrijum-kalijumove pumpe u eksperimentalnim modelima insulinske rezistencije, dijabetesa i kardiovaskularnih poremećaja (RS-MESTD-Basic Research (BR or ON)-173033)
DOI: 10.2174/1570161116666180209111826
ISSN: 1570-1611; 1875-6212
PubMed: 29424318
WoS: 000459679900009
Scopus: 2-s2.0-85062591993
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Radak, Đorđe J. AU - Atanasijević, Igor AU - Nešković, Mihailo AU - Isenović, Esma R. PY - 2019 UR - http://www.eurekaselect.com/159661/article UR - https://vinar.vin.bg.ac.rs/handle/123456789/8098 AB - Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease. T2 - Current Vascular Pharmacology T1 - The Significance of Pain in Chronic Venous Disease and its Medical Treatment VL - 17 IS - 3 SP - 291 EP - 297 DO - 10.2174/1570161116666180209111826 ER -
@article{ author = "Radak, Đorđe J. and Atanasijević, Igor and Nešković, Mihailo and Isenović, Esma R.", year = "2019", abstract = "Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.", journal = "Current Vascular Pharmacology", title = "The Significance of Pain in Chronic Venous Disease and its Medical Treatment", volume = "17", number = "3", pages = "291-297", doi = "10.2174/1570161116666180209111826" }
Radak, Đ. J., Atanasijević, I., Nešković, M.,& Isenović, E. R.. (2019). The Significance of Pain in Chronic Venous Disease and its Medical Treatment. in Current Vascular Pharmacology, 17(3), 291-297. https://doi.org/10.2174/1570161116666180209111826
Radak ĐJ, Atanasijević I, Nešković M, Isenović ER. The Significance of Pain in Chronic Venous Disease and its Medical Treatment. in Current Vascular Pharmacology. 2019;17(3):291-297. doi:10.2174/1570161116666180209111826 .
Radak, Đorđe J., Atanasijević, Igor, Nešković, Mihailo, Isenović, Esma R., "The Significance of Pain in Chronic Venous Disease and its Medical Treatment" in Current Vascular Pharmacology, 17, no. 3 (2019):291-297, https://doi.org/10.2174/1570161116666180209111826 . .